electroCore (ECOR) and Its Peers Head to Head Comparison

electroCore (NASDAQ: ECOR) is one of 47 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare electroCore to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for electroCore and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
electroCore 0 0 3 0 3.00
electroCore Competitors 226 650 1243 58 2.52

electroCore currently has a consensus target price of $21.50, suggesting a potential upside of 244.00%. As a group, “Electromedical equipment” companies have a potential upside of 19.93%. Given electroCore’s stronger consensus rating and higher possible upside, equities research analysts plainly believe electroCore is more favorable than its peers.

Insider and Institutional Ownership

14.5% of electroCore shares are held by institutional investors. Comparatively, 48.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.3% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares electroCore and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
electroCore N/A N/A N/A
electroCore Competitors -126.86% -58.01% -19.75%

Valuation and Earnings

This table compares electroCore and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
electroCore $990,000.00 -$55.82 million -5.25
electroCore Competitors $1.19 billion $88.57 million 17.32

electroCore’s peers have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

About electroCore

electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.